Literature DB >> 3908687

Technique for primate heterotopic cardiac xenotransplantation.

R E Michler, R P McManus, C R Smith, A N Sadeghi, E A Rose.   

Abstract

Heterotopic cardiac transplantation in the primate is a valuable method for the evaluation of immuno-suppressive regimens. This report describes our technique for heterotopic transplantation of cardiac grafts into the neck of baboons. Preliminary experience with cross-genus cardiac transplantation in the nonhuman primate is discussed.

Entities:  

Mesh：

Year:  1985        PMID： 3908687

Source DB:  PubMed          Journal:  J Med Primatol        ISSN： 0047-2565            Impact factor:   0.667


  4 in total

1.  Anti-Tac-H, a humanized antibody to the interleukin 2 receptor, prolongs primate cardiac allograft survival.

Authors:  P S Brown; G L Parenteau; F M Dirbas; R J Garsia; C K Goldman; M A Bukowski; R P Junghans; C Queen; J Hakimi; W R Benjamin
Journal:  Proc Natl Acad Sci U S A       Date:  1991-04-01       Impact factor: 11.205

2.  Immunoglobulin prevents complement-mediated hyperacute rejection in swine-to-primate xenotransplantation.

Authors:  J C Magee; B H Collins; R C Harland; B J Lindman; R R Bollinger; M M Frank; J L Platt
Journal:  J Clin Invest       Date:  1995-11       Impact factor: 14.808

3.  Intra-Abdominal Heterotopic Cardiac Xenotransplantation: Pearls and Pitfalls.

Authors:  Laura DiChiacchio; Avneesh K Singh; Joshua L Chan; Nicole M Shockcor; Tianshu Zhang; Billeta G Lewis; David Ayares; Philip Corcoran; Keith A Horvath; Muhammad M Mohiuddin
Journal:  Front Cardiovasc Med       Date:  2019-07-25

4.  Chimeric 2C10R4 anti-CD40 antibody therapy is critical for long-term survival of GTKO.hCD46.hTBM pig-to-primate cardiac xenograft.

Authors:  Muhammad M Mohiuddin; Avneesh K Singh; Philip C Corcoran; Marvin L Thomas Iii; Tannia Clark; Billeta G Lewis; Robert F Hoyt; Michael Eckhaus; Richard N Pierson Iii; Aaron J Belli; Eckhard Wolf; Nikolai Klymiuk; Carol Phelps; Keith A Reimann; David Ayares; Keith A Horvath
Journal:  Nat Commun       Date:  2016-04-05       Impact factor: 14.919
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.